Clinical trials: OHT - Ocular Hypertension
Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension
To investigate safety, efficacy, and the dose-response relationship of DE-104 in lowering intraocular pressure in Japanese and Non-Japanese subjects with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00868894
- Testing
- DE-104 medium concentration, DE-104 high concentration, 0.005% latanoprost
- Where
- 6 sites in United States
- Volunteers
- 49 people
- Sponsor
- Santen Inc.
Glaucoma, Angle-Closure
Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma
This study will evaluate the safety and IOP-lowering effectiveness of XEN in patients with Angle Closure Glaucoma.
- Trial name
- NCT03362931
- Testing
- XEN45
- Where
- 16 sites in Australia, Canada and 4 more
- Volunteers
- 65 people
- Sponsor
- Allergan
Glaucoma
Optical Coherence Tomography (OCT) Reference Data Collection Study (S-2015-3)
This prospective, single-arm clinical multicenter study intends to measure normal structural parameters of the optic nerve head, the peripapillary retinal nerve fiber layer, and the macula using the Heidelberg Spectralis OCT…
- Trial name
- NCT02785042
- Testing
- Heidelberg Spectralis OCT
- Where
- 8 sites in United States
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- Heidelberg Engineering GmbH
Glaucoma, Open-Angle, Ocular Hypertension
A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)
This study will evaluate the safety and efficacy of bimatoprost 0.01% in subjects with elevated intraocular pressure (IOP) due to primary open-angle glaucoma (POAG) or ocular hypertension (OH).
- Trial name
- NCT01594970
- Testing
- Bimatoprost 0.01%
- Where
- South Korea
- Volunteers
- 800 people
- Sponsor
- Allergan
Low Tension Glaucoma
Observational Study of the Long-term Effect of Latanoprost in Normal Tension Glaucoma
The purpose of this study is to assess the long-term efficacy and safety of latanoprost monotherapy in patients with normal tension glaucoma (NTG) using a prospective, observational design.
- Trial name
- NTG-X-PERT (NCT01209624)
- Volunteers
- 902 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open Angle Glaucoma (OAG), Ocular Hypertension (OH)
Evaluate Efficacy, Safety, Tolerability and Biodegradation of PA5346 Ocular Implant in Patients With Open-Angle Glaucoma or Ocular Hypertension
The goal of this clinical study is to learn how effective and safe is a single administration of PA5346 Ocular Implant for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT06964061
- Testing
- PA5436 Ocular Implant, 115mcg
- Where
- 2 sites in Australia
- Volunteers
- 12 people
- Sponsor
- PolyActiva Pty Ltd
Subjects With Primary Open-angle Glaucoma (POAG)
Prospective Evaluation of Open-Angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two iStents
The purpose of this study is to evaluate the intraocular pressure (IOP) lowering effect of two iStent devices in eyes of subjects with primary open-angle glaucoma
- Trial name
- NCT01252862
- Testing
- iStent
- Where
- Armenia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Glaukos Corporation
Graft vs Host Disease, Congenital Aniridia
Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation
The ARGOS-IO pressure sensor is intended to be implanted in the human eye in combination with Boston Keratoprosthesis (BKPro) surgery and to remain in place indefinitely.
- Conditions
- Graft vs Host Disease, Congenital Aniridia, Chemical Burns, Stevens-Johnson Syndrome
- Trial name
- NCT02945176
- Testing
- ARGOS-IO system
- Where
- 2 sites in Germany
- Volunteers
- 13 people
- Sponsor
- Implandata Ophthalmic Products GmbH
Primary Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.
To evaluate the safety and efficacy of PF-04217329.
- Trial name
- NCT00572455
- Testing
- PF-04217329 - Lowest Dose, PF-04217329 - Low Dose, PF-04217329 - Middle Dose
- Where
- 23 sites in United States
- Volunteers
- 318 people
- Sponsor
- Pfizer
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Intraocular Pressure (IOP) Reduction in Newly Diagnosed Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
This is an observational study and will evaluate IOP reduction in newly diagnosed patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians…
- Trial name
- NCT01628614
- Testing
- Standard of Care
- Where
- Spain
- Volunteers
- 4,812 people
- Sponsor
- Allergan
Open Angle Glaucoma, Ocular Hypertension
Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OH
This study is a double-masked, randomized, parallel group study in patients with open angle glaucoma or ocular hypertension. The aim of this study is to verify the efficacy of the fixed combination of Latanoprost 50 mcg / mL /…
- Trial name
- NCT01721707
- Testing
- Latanoprost+Brinzolamide combination, Latanoprost
- Where
- Brazil
- Sponsor
- Adapt Produtos Oftalmológicos Ltda.
Open Angle Glaucoma
STAR-LIFE Registry: STARflo Glaucoma Implant Clinical Experience Program
STARflo is a novel suprachoroidal Glaucoma Drainage Device (GDD), bleb-free, exhibiting anti-fibrotic properties. Release of this CE Marked implant has been limited to leading Glaucoma Centers in Europe.
- Trial name
- NCT02825264
- Testing
- STARflo Implant
- Where
- 9 sites in Belgium, France and 3 more
- Volunteers
- 70 people
- Sponsor
- iSTAR Medical
Primary Open-angle Glaucoma (POAG), Ocular Hypertension
Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma
Safety and tolerability of three different concentrations (0.1%, 03%, 0.6%) of the investigational SHP639 eye drops will be evaluated in participants with high eye pressure or primary open-angle glaucoma.
- Trial name
- NCT03131167
- Testing
- SHP639 (n=60)
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Shire
Open-angle Glaucoma
Hydrus Microstent for Refractory Open-Angle Glaucoma
The purpose of this study is to assess the safety and effectiveness of the Hydrus Microstent in patients with refractory open-angle glaucoma.
- Trial name
- SUMMIT (NCT03267134)
- Testing
- Hydrus Microstent, Ophthalmic surgery
- Where
- 20 sites in United States, Colombia and 3 more
- Volunteers
- 217 people
- Sponsor
- Ivantis, Inc.
Ocular Hypertension, Primary Open Angle Glaucoma
Efficacy and Safety of DNN.31.19.026 for Ocular Hypertension or Primary Open-Angle Glaucoma
This study aims to evaluate the safety and efficacy of DNN.31.19.026 compared with Cosopt® for the treatment of ocular hypertension or primary open-angle glaucoma.
- Trial name
- RENOIR (NCT07617532)
- Testing
- Product DNN.31.19.026, COSOPT®
- Volunteers
- 336 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Primary Open Angle Glaucoma, Ocular Hypertension
A Study of Efficacy and Safety of PHP-201 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
This is a phase 3 study to confirm the efficacy in reduction of intraocular pressure and safety of PHP-201 ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT04863365
- Testing
- PHP-201 ophthalmic solution
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- pH Pharma
Open-angle Glaucoma (OAG), Ocular Hypertension (OHT)
Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients
Qlaris Phase 2 clinical study investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in combination with latanoprost in open-angle glaucoma (OAG) and/or ocular hypertension (OHT) patients.
- Conditions
- Open-angle Glaucoma (OAG), Ocular Hypertension (OHT), Glaucoma
- Trial name
- NCT06249152
- Testing
- QLS-111, 0.015%, QLS-111, 0.030%, QLS-111, 0.075%
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Qlaris Bio, Inc.
Primary Open Angle Glaucoma, Ocular Hypertension
A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-
The purposes of this study are to determine the optimal concentration of DE-117 ophthalmic solution compared to the placebo ophthalmic solution and to determine if intraocular pressure reduction after 4 weeks of treatment with…
- Trial name
- NCT02623738
- Testing
- DE-117 ophthalmic solution low, DE-117 ophthalmic solution high, Latanoprost ophthalmic solution 0.005%
- Where
- Japan
- Volunteers
- 253 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Primary Open Angle Glaucoma
Phase I Dose Escalation Study to Investigate the Safety of ISTH0036 in Subjects With Glaucoma Undergoing Trabeculectomy
This study evaluates the addition of ISTH0036, an antisense oligonucleotide against TGF-β2, to glaucoma filtration surgery (trabeculectomy).
- Trial name
- NCT02406833
- Testing
- TGF-β2 antisense oligonucleotide, Trabeculectomy
- Where
- 3 sites in Germany
- Volunteers
- 13 people
- Sponsor
- Isarna Therapeutics GmbH
Glaucoma, Angle-Closure
Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients
This study will evaluate the safety and efficacy of patients switched from latanoprost monotherapy to a combination therapy of latanoprost with COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) for…
- Trial name
- NCT01151904
- Testing
- brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution, latanoprost
- Where
- Thailand
- Volunteers
- 17 people
- Sponsor
- Allergan